Literature DB >> 31345375

Leiomyosarcoma: Prognostic outline of a rare head and neck malignancy.

Tajindra Singh Saluja1, Janaki Iyer2, Satyendra Kumar Singh3.   

Abstract

Soft tissue sarcomas (STS) are mesenchymal malignant neoplasms with a broad spectrum of biologic behaviour. Most STS show predilection for extremities with rarity in head and neck. Leiomyosarcoma (LMS) is an extremely rare STS in head and neck due to the paucity of smooth muscles in this anatomical region. Owing to its rarity, diagnosis of LMS is often delayed or is often misdiagnosed. Our study aimed to evaluate clinico-demographic factors determining clinical course of primary head-neck LMS. Further, we also assessed cases of secondary head-neck LMS and LMS due to other causes to compare their clinical outcome with primary head-neck LMS. In primary LMS cases, intraoral LMS showed slightly better prognosis than extraoral LMS. Survival analysis revealed that prognosis of primary LMS was significantly better than secondary LMS. No significant difference in survival was seen between primary LMS and LMS due to other causes. These observations indicate that site of origin appears to determine the clinical behaviour of LMS. Results showed that size, recurrence and metastasis are important prognostic variables. Though large tumor size was associated with poor prognosis, tumor aggressiveness may not be directly proportional to its size. Surgical management with or without adjuvant therapy was associated with favourable outcome. As several factors are associated with prognostic outcome of head-neck LMS, multimodality therapy approach after careful analysis of various prognostic variables in each case on an individual basis is essential.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant therapy; Leiomyosarcoma; Prognosis; Site of origin; Survival

Mesh:

Year:  2019        PMID: 31345375     DOI: 10.1016/j.oraloncology.2019.06.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

Review 1.  Rare Diseases of the Oral Cavity, Neck, and Pharynx.

Authors:  Christoph A Reichel
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

Review 2.  Epstein-Barr Virus-Associated Smooth Muscle Tumors of Larynx: A Clinicopathologic Study and Comprehensive Literature Review of 12 Cases.

Authors:  Rumeal D Whaley; Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2021-04-23

3.  Leiomyoma and Leiomyosarcoma (Primary and Metastatic) of the Oral and Maxillofacial Region: A Clinicopathological and Immunohistochemical Study of 27 Cases.

Authors:  Gabriela Ribeiro de Araújo; Sara Ferreira Dos Santos Costa; Ricardo Alves Mesquita; Ricardo Santiago Gomez; Jean Nunes Dos Santos; Hélder Antônio Rebelo Pontes; Bruno Augusto Benevenuto de Andrade; Mário José Romañach; Michelle Agostini; Pablo Agustin Vargas; Cinthia Verônica Bardalez Lopez de Cáceres; Alan Roger Santos-Silva; Ana Carolina Prado Ribeiro; Thaís Bianca Brandão; Ramiro Alejandro Tomasi; Ruth Salomé Ferreyra; Oslei Paes de Almeida; Felipe Paiva Fonseca
Journal:  Head Neck Pathol       Date:  2021-06-09

4.  U2 small nuclear RNA auxiliary factor 2, transcriptionally activated by the transcription factor Dp-1/E2F transcription factor 1 complex, enhances the growth and aerobic glycolysis of leiomyosarcoma cells.

Authors:  Yuguo Li; Sihao Chen; Xin Zhang; Naiqiang Zhuo
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 5.  Neck subcutaneous nodule as first metastasis from broad ligament leiomyosarcoma: a case report and review of literature.

Authors:  Fiorella Cazzato; Angela D'Ercole; Graziano De Luca; Francesca B Aiello; Adelchi Croce
Journal:  BMC Surg       Date:  2020-11-25       Impact factor: 2.102

6.  Leiomyosarcoma of the Tracheostomy Site in a Patient with History of Laryngeal Squamous Cell Carcinoma.

Authors:  Zainub Ajmal; Abdul Moiz Khan; Lezah McCarthy; Allison Lupinetti; Syed Mehdi
Journal:  Case Rep Oncol       Date:  2021-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.